Palatin Technologies Announces Filing of International Patent Application for Lead Compound for Dry Eye Disease

Palatin Technologies announced the filing of an international patent application under the Patent Cooperation Treaty (PCT) directed to the composition of PL9643 and a related family of melanocortin agonist peptides. 

Palatin recently reported positive results in its phase 2 study of PL9643 for the treatment of dry eye disease (DED). Detailed study results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting. A phase 2/3 clinical trial with PL9643 for the treatment of DED is currently planned for mid-2021.

The PCT application for PL9643 establishes the base for the presumptive patent term, and if a patent is granted which claims priority to this application, could provide patent protection for PL9643, and any product in which PL9643 is the active pharmaceutical ingredient, out to 2041, excluding any additional term for patent adjustment or patent term extension. 

Palatin believes that the structure of PL9643 is novel and inventive. The International Search Authority will conduct a search and issue its Written Opinion on PL9643 and the related family of melanocortin agonist peptides, which will provide additional information on patentability of PL9643 and the related family. We anticipate filing patent applications in the United States, Europe and a number of additional regions and countries throughout the world.